HBK Investments’s BioCryst Pharmaceuticals BCRX Stock Holding History

HBK Investments’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-46,268	Closed	-$377K	–	646
2019 Q1	$377K	Buy	+46,268	New	+$396K	﹤0.01%	887
2016 Q2	–	Sell	-49,773	Closed	-$141K	–	955
2016 Q1	$141K	Buy	49,773 +30,073	+153%	+$133K	﹤0.01%	912
2015 Q4	$203K	Buy	+19,700	New	+$196K	﹤0.01%	912

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

HBK Investments's BCRX Position: Q2 2019 in Review

HBK Investments sold out of BioCryst Pharmaceuticals (BCRX) in Q2 2019, closing a stake of 46,268 shares — an estimated $377K sold.

HBK Investments first reported a position in BCRX in Q4 2015 and held it in 3 quarters. The position peaked at $377K in Q1 2019. 116 funds tracked by Wall St. Rank hold BCRX as of Q2 2019.

HBK Investments reported no remaining BioCryst Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
HBK Investments sold 46,268 BioCryst Pharmaceuticals shares in Q2 2019, an estimated $377K.
HBK Investments first reported a position in BioCryst Pharmaceuticals in Q4 2015 and held it in 3 quarters.
HBK Investments's BioCryst Pharmaceuticals position peaked at $377K in Q1 2019.
116 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2019.

Based on HBK Investments's 13F filing for Q2 2019, filed 14 Aug 2019.